United States Market for Rheumatoid Arthritis Pharmacotherapeutics

Additional Information

Report Excerpt

The market for rheumatoid arthritis (RA) pharmacotherapeutics that are prescribed as add-on therapy to background standards of care earned a revenue of approximately $million in 2011.

By 2017, total revenue for RA pharmacotherapeutics is expected to grow to $million.

The tumor necrosis factor (TNF) inhibitors Enbrel, Humira, and Remicade dominate the market as first-line standards of care and account for approximately percent of the revenue in 2011.

Amgen, Abbott, and Johnson & Johnson dominate the market almost equally, with Amgen maintaining a leading position by a small margin.

The TNF inhibitors are well entrenched and are expected to continue to dominate the market by the end of the forecast period, albeit to a lesser degree.

Novel oral antirheumatic drugs are anticipated to capture approximately percent of the market by 2017.

New biologics arriving to the market will impact TNF market share as well. However, novel orals and biologics are generally reserved for anti-TNF refractory patients.

The high cost of biologics make these essential therapies inaccessible to many patients, driving a need for less costly options without sacrificing safety or efficacy.

Although overall disease prevalence is not expected to change significantly, the eligible patient population is expected to grow due to anticipated changes in clinical practice.